2023 IKCS: North America
2023 IKCS: North America
Advertisement
Emily MenendezAdvanced Renal Cell Carcinoma | January 31, 2024
TKI monotherapy and TKI plus non-IO therapy was the most common subsequent treatment utilized after receiving IO-TKI.
Read More
Katy MarshallAdvanced Renal Cell Carcinoma | January 31, 2024
Researchers evaluated survival outcomes, demographic data, and clinical presentation.
Emily MenendezAdvanced Renal Cell Carcinoma | January 31, 2024
Past 12 months, the effectiveness and safety between nivolumab plus ipilimumab and pembrolizumab plus axitinib were similar.
Katy Marshall2023 IKCS: North America | November 13, 2023
Researchers compared the efficacy benefits of nivolumab plus cabozantinib with sunitinib alone.
Emily Menendez2023 IKCS: North America | November 13, 2023
The TRAE rates of 1L nivolumab plus ipilimumab were low and remained consistent relative to clinical trials.
Emily Menendez2023 IKCS: North America | November 13, 2023
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Katy Marshall2023 IKCS: North America | November 10, 2023
The researchers evaluated the radiographic information of patients with the primary tumor present.
Katy Marshall2023 IKCS: North America | November 10, 2023
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
Zachary Bessette2023 IKCS: North America | November 10, 2023
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
Zachary Bessette2023 IKCS: North America | November 10, 2023
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Zachary Bessette2023 IKCS: North America | November 10, 2023
Zanzalintinib shows promising antitumor activity and manageable toxicity in patients with previously treated advanced ccRCC.
Advertisement
Advertisement
Advertisement